NCT03202992View on ClinicalTrials.gov

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
HSIL, High-Grade Squamous Intraepithelial LesionsHuman Papilloma Virus InfectionHIV InfectionAnal CancerAnus Neoplasms
Interventions
DRUG

ABI-1968

Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Trial Locations (6)

2010

Research Center, Sydney

10011

Research Center, New York

27157

Research Center, Winston-Salem

32803

Research Center, Orlando

60614

Research Center, Chicago

94115

Research Center, San Francisco

Sponsors

Lead Sponsor

Antiva Biosciences
All Listed Sponsors
lead

Antiva Biosciences

INDUSTRY

NCT03202992 - Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | Biotech Hunter | Biotech Hunter